Abstract
Thirty-four patients with progressive low grade non-Hodgkin's lymphoma were treated with 1 microgram oral alfacalcidol daily. Complete response was seen in four patients and a partial response in four patients with an overall response rate of 24%. Median duration of response was 14 months. Disease stabilised in ten other patients (29%) and 16 patients (47%) had tumour progression. In the sub-group of patients with follicular, small-cleaved cell-lymphoma the overall response to treatment was 29%. Apart from one patient who had a mild transitory elevation of serum calcium there was no recorded toxicity from alfacidol. These results indicate that alfacalcidol has significant antitumour activity in patients with low grade non-Hodgkin's lymphoma of the follicular, small-cleaved cell type.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Raina, V., Cunningham, D., Gilchrist, N. et al. Alfacalcidol is a nontoxic, effective treatment of follicular small-cleaved cell lymphoma. Br J Cancer 63, 463–465 (1991). https://doi.org/10.1038/bjc.1991.108
Issue Date:
DOI: https://doi.org/10.1038/bjc.1991.108
This article is cited by
-
Vitamin D, disease and therapeutic opportunities
Nature Reviews Drug Discovery (2010)
-
A case–control study of ultraviolet radiation exposure, vitamin D, and lymphoma risk in adults
Cancer Causes & Control (2010)
-
Sun exposure, vitamin D receptor gene polymorphisms and risk of non-Hodgkin lymphoma
Cancer Causes & Control (2007)